Your browser doesn't support javascript.
loading
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.
Jain, Michael D; Jacobs, Miriam T; Gao, Feng; Nastoupil, Loretta J; Spiegel, Jay Y; Lin, Yi; Dahiya, Saurabh; Lunning, Matthew; Lekakis, Lazaros; Reagan, Patrick; Oluwole, Olalekan; McGuirk, Joseph; Deol, Abhinav; Sehgal, Alison R; Goy, Andre; Hill, Brian T; Andreadis, Charalambos; Munoz, Javier; Chavez, Julio C; Bennani, N Nora; Rapoport, Aaron P; Vose, Julie M; Miklos, David; Neelapu, Sattva S; Locke, Frederick L; Ghobadi, Armin.
Afiliación
  • Jain MD; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.
  • Jacobs MT; Division of Medical Oncology, Washington University School of Medicine and Siteman Cancer Center, St Louis, MO.
  • Gao F; Division of Medical Oncology, Washington University School of Medicine and Siteman Cancer Center, St Louis, MO.
  • Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Spiegel JY; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University Medical Center, Stanford, CA.
  • Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Dahiya S; Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD.
  • Lunning M; Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Lekakis L; Division of Transplant and Cellular Therapy, University of Miami Miller School of Medicine, Miami, FL.
  • Reagan P; Department of Medicine, Hematology/Oncology, University of Rochester Medical Center, Rochester, NY.
  • Oluwole O; Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN.
  • McGuirk J; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.
  • Deol A; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.
  • Sehgal AR; Division of Hematology/Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA.
  • Goy A; Lymphoma Division, John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ.
  • Hill BT; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.
  • Andreadis C; Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Munoz J; Division of Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ.
  • Chavez JC; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
  • Bennani NN; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Rapoport AP; Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD.
  • Vose JM; Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Miklos D; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University Medical Center, Stanford, CA.
  • Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Locke FL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.
  • Ghobadi A; Division of Medical Oncology, Washington University School of Medicine and Siteman Cancer Center, St Louis, MO.
Blood Adv ; 8(4): 1042-1050, 2024 Feb 27.
Article en En | MEDLINE | ID: mdl-38051550
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Linfoma de Células B Grandes Difuso / Receptores Quiméricos de Antígenos Límite: Humans Idioma: En Revista: Blood Adv Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Linfoma de Células B Grandes Difuso / Receptores Quiméricos de Antígenos Límite: Humans Idioma: En Revista: Blood Adv Año: 2024 Tipo del documento: Article